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Abstract
Lipidomics can offer an instant picture of the lipophilic metabolites from tissues and biofluids and can 
indicate the presence of different pathologies, such as hyperplasia or different types of cancers. Related to these 
pathologies, Prostate Serum Antigen (PSA), proved to have a low grade prediction for an accurate diagnosis. 
Meanwhile, untargeted or targeted metabolomics became a useful technology to discover new biomarkers for a 
better diagnostic. The aim of this study is to realize an adequate procedure based on liquid chromatography coupled 
with mass spectrometry (HPLC-MS) to determine the profile  of lipids from blood serum, followed by adequate 
biostatistics. Blood samples, obtained from healthy men and patients with prostate benign hyperplasia,  post-biopsy 
cancer and post-surgery cancer were processed for extraction of lipids with Bligh & Dyer method, and subjected to 
HPLC–ESI(+)QTOF-MS measurements. TofControl 3.2 and Data Analysis 4.2 software (Bruker Daltonics) were used 
for the control of the instrument and data processing. To process the matrix data, Profile Analysis 2.0 software 
was applied for alignment and advanced bucketing and then, the multivariate analysis (PCA and Cluster Analysis) 
using Unscrambler 10.1 software. The statistical unsupervised analysis based on PCA scores and loadings, showed 
a good discrimination between the two cancer groups of patients (after biopsy and after surgery) and for benign 
hyperplasia patients against controls, based on the comparison of peak areas. The molecules responsible for such 
discriminations were identified to be mainly represented by lysophospatidylcholines. By Cluster Analysis, the 
dendograms showed good statistical clustering of samples, especially for cancer patients against controls and less 
clustered for hyperplasia.  Finally, one can consider that molecules belonging to phospholipid family and diacyl /
triacylglycerides or ceramides or carnitines can be considered potential biomarkers for hyperplasia and prostate 
cancer.
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INTRODUCTION   
Prostate cancer (PCa) became a common malignancy and the second leading cause of 
cancer deaths in men (Ferlay et al., 2013). Recent 
studies of metabolite profiling in the prostate 
tissue, in blood and urine of patients with PCa 
showed the potential of metabolomics to improve 
diagnosis and provide answers regarding tumor 
invasiveness (Osl et al., 2008; Lochov et al. 2010; Teahan et al. 2011; Zhang et al. 2014), a better 
detection and prediction being crucial for the 
patient survival.
Metabolic biomarkers are small molecules 
(with molecular weight under 5000 Da) specific 
to tissues, cells or biofluids, wich can indicate 
the presence and evolution of a certain metabolic 
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pathway or pathology, or to reflect the effects of 
applied treatments (Mishra and Verma, 2010). 
Few prostate cancer biomarkers for early 
stage detection are available, the most known 
being the Prostate Serum Antigen (PSA) an 
androgen regulated protein biomarker. By its  low 
predictability, PSA cannot have a good prognostic 
value, can identify less then 70% of PCa, does 
not distinguish sufficiently between malignant 
and benign diseases (prostatitis and prostatic 
hypertrophy) (Vicini et al., 2005) 
New reliable, predictive biomarkers are neces-sary for early and strength diagnosis beside the 
biopsy, as a gold standard (Verma and Banerjee 
2015). 
Lipidomics, a branch of metabolomics spe-
cifically focuses on lipids and their metabolites 
in physiologic or pathologic states (Han, 2009). 
These molecules are the structural component 
of the cell membrane embedded with various 
protein complexes with different functions in cell 
signaling as a substrate, product or co-factor in 
the biochemical reactions. Lipids are involved in a 
variety and complex physiological processes like signaling membrane, reserve energy and endocrine 
action (Feng and Prestwich, 2005; Wenk, 2005; 
Wolf and Quinn, 2008). Therefore, lipidomics  can 
be used to improve the diagnostic and prognosis 
by small lipid metabolites which are expected to 
reflect the alterations in the cellular and tissular 
metabolism (Punglia 2003).  Recent studies show 
the lipidomic profile changes in the etiology and 
prognosis of cancer pathology (Cvetkovic et al., 
2009; Lo et al., 2007). Metabolomic fingerprints 
of lipids represents a signature yet established in 
cancer biology (DeBerardinis et al., 2008; Santos 
and Schulze 2012). Modified proteins by lipids and 
bioactive lipids assist network signaling of many 
cancer pathologies (Wymann and Schneiter, 2008)
Lipidomic analysis defines the phenotype of 
cells or tissues as a response to the environment 
or genetic changes, the level of lipids being 
fundamental for a defined genetic function 
(Van Meer, 2005; Villas-Boas and Gombert, 
2006). Lipidomic biomarkers can also identify 
compounds of cytotoxic, aterogenic, mutagenic 
and carcinogenic origin (Seppänen-Laakso and 
Oresic, 2009). 
Analytical platforms based on Chromatog-
raphy coupled with Mass Spectrometry (MS) are 
frequently used in Lipidomics to provide the sen-
sitive and reproducible detection of hundreds 
metabolites in a single biofluid or tissue sample. 
Biofluids, such as blood serum and plasma are the 
most frequent materials utilized for clinical diag-
nosis, to measure the level of lipids used for pre-
diction of cancer progression (Jelonek et al., 2013; 
Ghahremanfard et al., 2015; Chawda et al., 2011).
Many protocols for serum- and plasma-based 
metabolic profiling apply gas chromatography–
MS (GC-MS) and high performance liquid 
chromatography (HPLC) coupled with MS. Such 
protocols include biofluid collection, sample 
preparation, data acquisition, data pre-processing 
and quality assurance (Dunn et al., 2011)
The most suitable tool to investigate small lipid 
metabolites as potential biomarkers is HPLC-MS 
due to its high sensitivity, specificity, ease handling 
of samples and large number of metabolites 
detected (Gika et al., 2014). Two strategies can 
be applied: untargeted metabolomics which 
measures all the metabolites in a sample, screening 
a specific sample fingerprint and/or the targeted metabolomics that measure a limited number of 
metabolites and quantify their concentrations 
(Han and Gross, 2003; Dunn et al., 2011).  
The aim of this study is to determine a lipidomic 
profile of lipids from the blood serum of patients 
with benign hyperplasia and prostate cancer, 
based on liquid chromatography coupled with 
mass spectrometry (HPLC-MS) and unsupervised biostatistics to identify the discriminations 
between the pathological and healthy state of 
lipidomic phenotypes.
MATERIALS AND METHODS   
Human blood samples were collected 
according to a protocol approved by the Bioethical Commission Board from the University of Medicine 
and Pharmacy “Iuliu Hatieganu” Cluj-Napoca 
and after the patients’ written consent prior to 
be included in this study. All blood samples were 
collected from patients registered at the Municipal 
Clinical Hospital Cluj-Napoca, Romania (in 2015) 
previously diagnosed and histologically classified 
with benign prostatic hyperplasia (BPH) (n = 40, 
mean age 63.92±7.8 years old), prostate sample 
taken before biopsy (PCa-b) (n=51, mean age 
65.67±7.5 years old), prostate sample taken after 
surgery  (PCa-s) (n=38, mean age 66.05±5.5 years 
old),  comparatively with control subjects (n = 12, 
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mean age 50±6.4 years old). The pathologic groups 
BPH, PCa-b, PCa-s were characterized previously by 
different clinical parameters, including PSA values 
and Gleason scores (data not shown). The blood 
serum was obtained by standard procedure after 
coagulation for 30 minutes at room temperature 
and centrifugation, 10 min at 2000 g.
Lipids were extracted according to Bligh and 
Dyer method (Bligh and Dyer, 1959). A volume 
of 0.1 ml serum was mixed with 0.2 ml methanol, 
then vortexed for 20 s, and 1.66 ml chloroform 
was added and vortexed for 20 s. Finally, a volume 
of  0.1 ml water was added to induce the phase 
separation and centrifugated at 8000 g for 10 
min. The lipid-chloroform phase was collected 
and evaporated, then reconstituted in 500 µl of 
chromatographic eluent ACN/IPA/H2O (65:30:5, 
v/v) and ultrasonicated for 10 min . After filtration 
through 0.2 µm PTFE filters, the LC-MS analysis 
was performed.
Aliquots of 5 µl of each extract were subjected 
to HPLC-MS on a Bruker  DaltonicsMaXis Impact 
equipment with a Thermo Scientific HPLC UltiMate 
3000 system including a quaternary pump 
delivery system DionexUltiMate and MS detection. 
The separation was done on a C18 reverse-phase 
column [5µm, 2.1 x 100 mm], (Acclaim, Dionex) 
maintained at 55°C.
The mobile phases were: A: water: acetonitrile 
(60:40) containing 0.1% formic acid and 10 mM 
ammonium formate and  B: isopropyl alcohol: 
acetonitrile (90:10) containing 0.1% formic acid 
and 10 mM ammonium formate. The gradient 
used: 75% A: 25% B followed by linear gradient 
to 50% A: 50% B at 4 min, then a gradient from 
50% A to  3% A: 97% B at 19 min, isocratic on 3% 
A: 97% B for 4 min and then returned to the initial 
condition 75% A: 25% B at 24 min for 4 min. The 
flow rate was 0.260 ml/min.
Mass spectrometry was performed on a 
Bruker Daltonics MaXis Impact Q-TOF operating 
in positive ion mode (ESI+). The mass range was 
set between 50-1000 m/z. The nebulizing gas 
pressure was set at 2.8 bar, the drying gas flow 
at 12 L/min, the drying gas temperature at 300 
°C. Before each chromatographic run, a calibrant 
solution of sodium formate was injected. 
TofControl 3.2 and Data Analysis 4.2 (Bruker 
Daltonics) software were used for the control of 
the instrument and data processing. 
The algorithm Find Molecular Features (FMF) 
was applied on data in Data Analysis software 
and then Profile Analysis 2.0 (Bruker) for data 
pre-processing, alignment, bucketing (retention 
time range from 1’ to 28’ was used for bucket 
generation) and normalization (Sum of bucket 
values in analysis algorithm) was done to obtained 
proper matrix for biostatistics and bioinformatics 
analysis. Advance bucketing was done using the 
parameters obtained automatically from the time 
alignment. Only metabolites detected in more than 
80% of the samples were selected to obtain the 
Serum Lipidomic Biomarkers from Patients with Prostate Pathology Identified by High Performance Liquid Chromatography
Fig.1. Comparative image of  Dissected chromatograms of serum samples  from C ( control), PCa-b (Biopsy can-
cer), PCa-s ( Surgery cancer)  and BPH
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matrix utilized for the unsupervised biostatistics 
and multivariate analysis, by Principal Component 
Analysis (PCA) and Cluster Analysis (CA). The 
Unscrambler X 10.1 (CAMO Software AS, Norway) 
software was also used,  importing the matrix 
data and applying the multivariate analysis like 
PCA and CA. The distance method used for CA was 
Euclidean and the linkage method was Average.
RESULTS AND DISCUSSION   
Chromatographic profile of serum lipids  
Fig.1 shows the fingerprints of the blood 
serum lipid extracts, comparatively, from C ( 
control), PCa-b (Biopsy cancer), PCa-s ( Surgery 
cancer)  and BPH patients.
The number of lipid molecules which were 
separated by HPLC ranged from 62 (BPH) to 
123, separated in 23-25 min. Around six groups 
of molecules were separated, according to their 
polarity and molecular weight: very polar lipids 
and non-lipid molecules from min 1 to 5, polar 
lipids from min 6 to 9 ( group 2), semipolar lipids 
from min 12-15 (group 3), neutral lipids from min 
12 to 16 ( group 4) and nonpolar lipids from min 
20 to 23 ( group 5). The identification of these 
lipids was done by comparing their ESI +  m/z 
values with the values registered in Lipidomics 
Gateway (http://www.lipidmaps.org/ ) and 
Human Metabolomic Data Base (http://www.
hmdb.ca/).
Nontargeted, unsupervised analysis of 
data by Principal Component Analysis
Using the Uncrambled software and the 
optimized parameters for data processing ( see 
Materials and Methods), the statistics applied for 
data inputs was Principal Component Analysis 
(PCA). In Fig. 2 there are shown the PCA scores 
(upper graphics) and loadings (down graphics), 
to discriminate between biopsy cancer vs Control 
(a), surgery cancer vs Control (b), Hyperplasia vs 
Control (c). 
Fig. 2a shows 2 subgroups of biopsy cancer 
patients, one group having a fingerprint close 
to controls (marked with red circles) and one 
subgroup significantly different. The loadings 
graphic shows that 3 molecules with m/z values of 
282.281, 520.344 and 524.345 may be responsible 
for these differences. 
Fig. 2b shows also 2 subgroups, but the second 
one less abundant,  of surgery cancer patients, 
one group having a fingerprint close to controls 
(marked with red circles) and a secondary, less 
abundant subgroup significantly different. The 
loadings graphic shows that molecules with m/z 
LAZĂR et al
Fig. 2. PCA scores and loadings of pathological groups ( biopsy cancer, surgery cancer, hyperplasia) vs control 
group
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values of 256.265, 381.300, 353.268, 520.344, 
522.360 and 524.345  are responsible for these 
differences. 
Fig. 2c shows also 2 subgroups, a first group 
less abundant,  having a fingerprint close to 
controls (marked with red circles) and a secondary, 
less abundant subgroup significantly different. 
The loadings graphic shows that molecules with 
m/z values of 256.265, 282.281, 353.268, 520.344, 
522.360 and 524.345  are responsible for these 
differences.Finally, according to these data eleven 
molecules were selected as potential biomarkers, 
in all cases three similar molecules with m/z values 
of 520.344, 522.360 and 524.345 (corresponding 
to 3 successive C18-lysophosphatidyl cholines) 
were responsible for the discriminations between 
the pathologic and control groups.  The molecules 
with m/z=282.281 were different in biopsy and 
Serum Lipidomic Biomarkers from Patients with Prostate Pathology Identified by High Performance Liquid Chromatography
Relative distance
0 1 2 3 4 5 6 7 8 9 10
M6
M8
M4
M7
M2
M1
M3
CB11
CB90
CB1
CB54
M12
CB81
CB8
CB40
CB41
CB43
CB47
CB48
CB58
CB65
CB12
CB13
CB25
CB95
CB76
CB89
CB17
CB33
CB39
CB91
CB9
M11
CB14
CB22
CB80
CB88
CB23
CB37
CB2
CB82
CB27
CB42
CB50
CB79
CB61
M13
CB28
CB36
CB55
CB74
CB78
CB67
M10
CB51
CB72
CB92
CB93
CB60
CB77
CB5
CB73
Average linkage clustering using Squared Euclidean distance
Fig. 3. Cluster dendogram based on average linkage method using Squared Euclidean distance of biopsy group 
(CB) and controls (M). 
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Fig. 4. Cluster dendogram based on average linkage method using Squared Euclidean distance of surgery group 
(CO) and controls (M).
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hyperplasia groups, while molecules with m/z 
= 256.265, 381.300, 353.268 were significantly 
different in surgery cancer group vs controls.
Nontargeted, supervised interpretation of 
data: Cluster Analysis 
The Hierarchial Cluster Analysis processed 
the  data obtained from FMF matrix considering 
an advanced bucketing. According to Fig.3, for 
biopsy cancer (marked CB) two clustering groups 
were obtained, in accordance with the PCA data ( 
Fig.2a). For controls, a  good clustering was found 
also, excepting M10 and M11. 
According to Fig.4, for surgery cancer group 
(marked CO) there were found more dispersed 
clustering groups, the CO samples being clustered 
in four subgroups. 
According to Fig.5, for hyperplasia group 
(marked H) there were found more dispersed 
clustering groups, spread among the controls. The 
significance of this clustering is that not so many 
statistical significant differences can be found 
between the hyperplasia and control groups.
Identification of specific lipid biomarkers 
of the pathologic groups 
Using the untargeted biostatistics processed 
by Profile Analysis, there were identified 
LAZĂR et al
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Fig. 5. Cluster dendogram based on average linkage method using Squared Euclidean distance of Hyperplasia 
group (H) and controls (M).
Tab. 1. Tentative assignement of main  molecules corresponding specifically to pathologic groups 
(for abbreviations, see the text).
m/z Tentative assignment Specific to
316.322 Eicosanoic acid or  decanoylcarnitine PCa-s
369.352 Tetracosanoic acid PCa-b, BPH
415.211 Ascorbyl palmitate PCa-s, PCa-b,  BPH
432.240 N-stearoyl phenylalanine PCa-b
607.570 DG(16:0/0:0/18:2n6) PCa-b
666.627 PS(O-16:0/12:0) PCa-b, BPH
582.582 Ceramide(d14:1/22:0(2OH)) or Ceramide (d16:1/20:0(2OH)) PCa-s
806.573 PC(16:0/22:6) or  PC(18:1/20:5) or  PC(18:2/20:4) PCa-s
801.561 TG(16:1/14:0/18:2) or TG(16:0/14:0/18:3) BPH
760.589 PC(16:0/18:1) or PC(16:1/18:0) BPH
810.604 PC(18:0/20:4) or  PC(18:1/20:3) or PC(18:2/20:2) BPH
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the specific molecules, related to a specific 
pathology, based on the peak areas and m/z 
values (Table 1). The molecules with m/z values 
of 316.3227 (corresponding to eicosanoic acid 
or decanoylcarnitine), 582.582 (ceramides)  and 
806.573 (corresponding to PC(16:0/22:6) or 
PC(18:1/20:5) or PC(18:2/20:4) are specific to 
surgery cancer (PCa-s).  The molecules with m/z values of  432.240 (N-stearoyl phenylalanine) 
and 607.570 DG(16:0/0:0/18:2n6) are specific 
to biopsy cancer (PCa-b). The molecules with 
m/z values of 801.561 (TG(16:1/14:0/18:2), 
TG(16:0/14:0/18:3)), 760.589 PC(16:0/18:1) 
or  PC(16:1/18:0),  810.604 (PC(18:0/20:4) or 
PC(18:1/20:3) or PC(18:2/20:2) are specific 
to hyperplasia (BPH). The molecules 369.352 
(Tetracosanoic acid) and 666.627 (PS(O-
16:0/12:0) are specific to groups of biopsy cancer 
(PCa-b) and hyperplasia (BPH). The molecule with 
m/z= 415.211 (Ascorbyl palmitate) is common to 
all groups.
CONCLUSION   
By an advanced technique HPLC coupled 
with Mass Spectrometry and an optimized data 
processing and analysis we were able to separate 
and identify hundreds if lipid molecules in blood 
serum, as candidates for prostate pathologies 
(hyperplasia and cancer). 
The statistical unsupervised analysis based on PCA scores and loadings, using  the Uncrambled 
softaware, showed a good discrimination between 
the two cancer groups of patients (after biopsy 
and after surgery) and for benign hyperplasia 
patients against controls, based on the comparison 
of peak areas. The molecules responsible for such 
discriminations were identified to be mainly 
represented by lysophospatidylcholines. By 
Cluster Analysis, the dendograms showed good 
statistical clustering of samples, especially for 
cancer patients against controls and less clustered 
for hyperplasia.  
Using a Profile Analysis software,  the 
identification of lipid biomarkers  for specific 
pathologic groups was possible. Molecules 
belonging to phospholipid family and diacyl /triacylglycerides or ceramides or carnitines can be 
considered potential biomarkers for hyperplasia 
and prostate cancer. 
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